-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

Baird Upgrades Allogene Therapeutics to Outperform From Neutral, Price Target at $12

Baird Upgrades Allogene Therapeutics to Outperform From Neutral, Price Target at $12

MT Newswires · 01/06/2023 02:59